(CercleFinance.com) – Sanofi indicates that it has been informed by the United States FDA that the launch of the trial in real conditions of use, planned to support its application for the transfer of Cialis to the self-medication market, had deferred for reasons related to the trial protocol.
No patients have yet been enrolled in this trial. Sanofi continues to work with the FDA to advance the Cialis transfer program in the self-medication market and will soon engage in a dialogue with the agency to determine the follow-up.
Currently subject to medical prescription, Cialis comes in the form of a tablet and is indicated for the treatment of erectile dysfunction and/or the signs and symptoms of benign prostatic hyperplasia.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
